Leaflet LEUCOMAX 300mcg lyophilisate for solution for injection+solvent


Indicated for: neutropenia

Route of administration: injectable

Substance: molgramostim (granulocyte colony-stimulating factor)

ATC: L03AA03 (Antineoplastic and immunomodulating agents | Immunostimulants | Colony stimulating factors)

Molgramostim is a medication used for the treatment of certain rare lung conditions, such as autoimmune pulmonary alveolar proteinosis. It is a recombinant form of granulocyte-macrophage colony-stimulating factor (GM-CSF), which helps improve lung function by stimulating the clearance of accumulated proteins in the alveoli.

The medication is administered via inhalation under the supervision of a specialist. It is effective in reducing symptoms and improving the quality of life for patients with this rare condition.

Side effects may include coughing, difficulty breathing, fever, or fatigue. In rare cases, severe allergic reactions may occur. It is important to follow your doctor's instructions and monitor your response to treatment.

Consult your doctor to discuss the benefits and risks of treatment with Molgramostim. Regular monitoring is essential to ensure the therapy's effectiveness.

General data about LEUCOMAX 300mcg

  • Substance: molgramostim
  • Date of last drug list: 01-07-2013
  • Commercial code: W12130001
  • Concentration: 300mcg
  • Pharmaceutical form: lyophilisate for solution for injection+solvent
  • Quantity: 1
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Concentrations available for molgramostim

  • 150mcg
  • 300mcg